Inhibitory function of p21(Cip1/WAF1) in differentiation of primary mouse keratinocytes independent of cell cycle control

Science

Volumn 280, Issue 5366, 1998, Pages 1069-1072

  Di Cunto, Ferdinando ^a,b   Topley, Gabrielle ^a   Calautti, Enzo ^a   Hsiao, Jimmy ^a   Ong, Lydia ^a   Seth, Prem K ^c   Dotto, G Paolo ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; MESSENGER RNA; PROTEIN P21; 2,3-EPOXYSUCCINIC ACID; ACETYLCYSTEINE; ACETYLLEUCYL LEUCYL NORLEUCINAL; ACETYLLEUCYL-LEUCYL-NORLEUCINAL; CDKN1A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; DRUG DERIVATIVE; ENZYME INHIBITOR; EPOXYSUCCINIC ACID; INVOLUCRIN; LACTACYSTIN; LEUPEPTIN; LORICRIN; MEMBRANE PROTEIN; PROTEIN PRECURSOR; SUCCINIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL CYCLE PHASE; CELL DIFFERENTIATION; CONTROLLED STUDY; GROWTH INHIBITION; KERATINOCYTE; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOVIRUS; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CELL CYCLE; CYTOLOGY; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; MUTATION; NEWBORN; PHYSIOLOGY; PROMOTER REGION; VIROLOGY;

ACETYLCYSTEINE; ADENOVIRIDAE; ANIMALS; ANIMALS, NEWBORN; CELL CYCLE; CELL DIFFERENTIATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; KERATINOCYTES; LEUPEPTINS; MEMBRANE PROTEINS; MICE; MUTATION; PROMOTER REGIONS (GENETICS); PROTEIN PRECURSORS; RNA, MESSENGER; SUCCINATES; TRANSFECTION;

EID: 0032523239     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.280.5366.1069     Document Type: Article

References (29)

1. J. W. Harper, Cancer Surv. 29, 91 (1997).
2. W. S. El-Deiry et al., Cancer Res. 55, 2910 (1995); A. L. Gartel et al., Exp. Cell Res. 227, 171 (1996); F. Ponten, B. Berne, Z. P. Ren, M. Nister, J. Ponten, J. Invest. Dermatol. 105, 402 (1995).
3. W. S. El-Deiry et al., Cancer Res. 55, 2910 (1995); A. L. Gartel et al., Exp. Cell Res. 227, 171 (1996); F. Ponten, B. Berne, Z. P. Ren, M. Nister, J. Ponten, J. Invest. Dermatol. 105, 402 (1995).
4. W. S. El-Deiry et al., Cancer Res. 55, 2910 (1995); A. L. Gartel et al., Exp. Cell Res. 227, 171 (1996); F. Ponten, B. Berne, Z. P. Ren, M. Nister, J. Ponten, J. Invest. Dermatol. 105, 402 (1995).
5. I. Delalle and V. S. Caviness Jr., Soc. Neurosci. Abstr. 22, 254 (1996).
6. H. Hennings et al., Cell 19, 245 (1980).
7. C. Missero et al., Proc. Natl. Acad. Sci. U.S.A. 92, 5451 (1995).
8. C. Missero, F. Di Cunto, H. Kiyokawa, A. Koff, G. P. Dotto, Genes Dev. 10, 3065 (1996).
9. L. Li, T. Tennenbaum, S. H. Yuspa, J. Invest. Dermatol. 106, 254 (1996).
10. T. M. Guadagno, M. Ohtsubo, J. M. Roberts, R. K. Assoian, Science 262, 1572 (1993).
11. F. M. Watt, P. W. Jordan, C. H. O'Neill, Proc. Natl. Acad. Sci. U.S.A. 85, 5576 (1988).
12. 6 cells/ml. Samples (4 ml) of the suspension were then plated in 60-mm petri dishes and incubated for the indicated times.
13. M. V. Blagosklonny, G. S. Wu, S. Omura, W. S. El-Deiry, Biochem. Biophys. Res. Commun. 227, 564 (1996); C. G. Maki, J. M. Huibregtse, P. M. Howley, Cancer Res. 56, 2649 (1996); C. G. Maki and P. M. Howley, Mol. Cell. Biol. 17, 355 (1997).
14. M. V. Blagosklonny, G. S. Wu, S. Omura, W. S. El-Deiry, Biochem. Biophys. Res. Commun. 227, 564 (1996); C. G. Maki, J. M. Huibregtse, P. M. Howley, Cancer Res. 56, 2649 (1996); C. G. Maki and P. M. Howley, Mol. Cell. Biol. 17, 355 (1997).
15. M. V. Blagosklonny, G. S. Wu, S. Omura, W. S. El-Deiry, Biochem. Biophys. Res. Commun. 227, 564 (1996); C. G. Maki, J. M. Huibregtse, P. M. Howley, Cancer Res. 56, 2649 (1996); C. G. Maki and P. M. Howley, Mol. Cell. Biol. 17, 355 (1997).
16. V. J. Palombella, O. J. Rando, A. L. Goldberg, T. Maniatis, Cell 78, 773 (1994); G. Fenteany et al., Science 268, 726 (1995).
17. V. J. Palombella, O. J. Rando, A. L. Goldberg, T. Maniatis, Cell 78, 773 (1994); G. Fenteany et al., Science 268, 726 (1995).
18. A. J. Barrett et al., Biochem. J. 201, 189 (1982).
19. D. Katayose, R. Wersto, K. H. Cowan, P. Seth, Cell Growth Differ. 6, 1207 (1995).
20. INK4a is based on a vector identical to that used for the p21 adenovirus (74). The third adenovirus expressing the p21 protein with a COOH-terminal truncation was developed by another laboratory (16) but has a backbone very similar to that of the other viruses [G. W. G. Wilkinson and A. Akrigg, Nucleic Acids Res. 20, 2233 (1992)]. In all cases, infection was performed for 1 hour in serum-and epidermal growth factor-free low-calcium medium; keratinocytes were then incubated in fully supplemented low-calcium medium (5) for 24 hours and collected (for the studies of attached versus detached populations) or switched to high-calcium medium (2 mM) for the indicated times.
21. N. S. Prabhu et al., Clin. Cancer Res. 2, 1221 (1996).
22. Primary keratinocytes were cotransfected (5) with a green fluorescent protein expression plasmid together with a plasmid encoding either human wild-type p21 or a p21 mutant with a deletion of the COOH-terminal domain (78). Transfected cells were incubated in low-calcium medium for 72 hours, and the spontaneously detached cells were analyzed by immunofluorescence with antibodies to loricrin (6). Promoter activity assays were as described [J. L. Brissette, J. Lee, J. Kamimura, D. Lee, G. P. Dotto, Genes Dev. 10, 2212 (1996)].
23. J. Chen, P. Saha, S. Kornbluth, B. D. Dynlacht, A. Dutta, Mol. Cell. Biol. 16, 4673 (1996).
24. J. Chen, P. K. Jackson, M. W. Kirschner, A. Dutta, Nature 374, 386 (1995); J. Luo and J. Massague, ibid. 375, 159 (1995).
25. J. Chen, P. K. Jackson, M. W. Kirschner, A. Dutta, Nature 374, 386 (1995); J. Luo and J. Massague, ibid. 375, 159 (1995).
26. L. S.-H. Chuang et al., Science 277, 1996 (1997).
27. J. LaBaer et al., Genes Dev. 11, 847 (1997).
28. J. Shim, H. Lee, J. Park, H. Kim, E. J. Choi, Nature 381, 804 (1996).
29. We thank W. S. El-Deiry for adenoviruses, C. Craig for help in constructing the Ad-p16 virus, C. Schneider and E. Harlow for antibodies, D. R. Roop for the loricrin cDNA probe, and A. Dutta for the p21 mutants. Supported by NIH grants AR39190 and CA16038 (G.P.D.) and, in part, by the Cutaneous Biology Research Center through the Massachusetts General Hospital/Shiseido Co. Ltd. Agreement.